CoChat

Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer

Open access
Nakamura, Yoshiaki, Yoshino, Takayuki · 2018 · The Oncologist

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Abstract

Multiple genomic changes caused by clonal evolution induced by therapeutic pressure and corresponding intratumoral heterogeneity have posed great challenges for personalized therapy against metastatic colorectal cancer (mCRC) in the past decade. Liquid biopsy has emerged as an excellent molecular diagnostic tool for assessing predominant spatial and temporal intratumoral heterogeneity with minimal invasiveness. Previous studies have revealed that genomic alterations in RAS, BRAF, ERBB2, and MET, as well as other cancer-related genes associated with resistance to anti-epidermal growth factor receptor (EGFR) therapy, can be analyzed with high diagnostic accuracy by circulating tumor DNA (ctDNA) analysis. Furthermore, by longitudinally monitoring ctDNAs during anti-EGFR therapy, the emergence of genomic alterations can be detected as acquired resistance mechanisms in specific genes, mainly those associated with the mitogen-activated protein kinase signaling pathway. Analysis of ctDNA can also identify predictive biomarkers to immune checkpoint inhibitors, such as mutations in mismatch repair genes, microsatellite instability-high phenotype, and tumor mutation burden. Some prospective clinical trials evaluating targeted agents for genomic alterations in ctDNA or exploring resistance biomarkers by monitoring of ctDNA are ongoing. To determine the value of ctDNA analysis for decision-making by more accurate molecular marker-based selection of patients and identification of resistance mechanisms to targeted therapies or sensitive biomarkers for immune checkpoint inhibitors, clinical trials must be refined to evaluate the efficacy of study treatment in patients with targetable genomic alterations confirmed by ctDNA analysis, and resistance biomarkers should be explored by monitoring ctDNA in large-scale clinical trials. In the near future, ctDNA analysis will play an important role in precision medicine for mCRC. Implications for Practice: Treatment strategies for metastatic colorectal cancer (mCRC) are determined according to the molecular profile, which is confirmed by analyzing tumor tissue. Analysis of circulating tumor DNA (ctDNA) may overcome the limitations of tissue-based analysis by capturing spatial and temporal intratumoral heterogeneity of mCRC. Clinical trials must be refined to test the value of ctDNA analysis in patient selection and identification of biomarkers. This review describes ctDNA analysis, which will have an important role in precision medicine for mCRC.

Overview

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2017-0621

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 83 references

Research works printed but not linked: 1

  1. Corcoran, 2016, Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600Er. g hepateRAFm) metastatic colorectal cancer (mCRC), Ann Oncol, 27, 4550

Cited by

See all 61

Metadata

Authors
Nakamura, Y., & Yoshino, T.
Affiliations
National Cancer Centre Japan (JP)
Corresponding author
Yoshino, Takayuki
Venue
The Oncologist
Published
2018-04-26
Volume
23
Issue
11
Pages
1310-1318
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2801333751
Cited by
61
References
83
Citations by year
2026: 3 · 2025: 5 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 16 · 2020: 15 · 2019: 2 · 2018: 1
FWCI
0.89
Type
journal article
Language
en
Open access
Locations
  • The Oncologist (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
circulating tumor DNA, liquid biopsy, metastatic colorectal cancer, intratumoral heterogeneity, clonal evolution, anti-EGFR therapy resistance, RAS mutations, BRAF mutation, MET amplification, ERBB2, MAPK signaling, immune checkpoint inhibitors, predictive biomarkers, mismatch repair genes, microsatellite instability, tumor mutational burden, precision medicine, longitudinal ctDNA monitoring
MeSH terms
Circulating Tumor DNA, Female, Humans, Neoplasm Metastasis, Colorectal Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1634/theoncologist.2017-0621
The paper
Nakamura, Y., & Yoshino, T. (2018). Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. The Oncologist. https://doi.org/10.1634/theoncologist.2017-0621

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.